How do ipamorelin and tesamorelin differ?
Ipamorelin engages the ghrelin receptor (GHSR-1a) on pituitary somatotroph cells; tesamorelin engages the parallel GHRH receptor on the same somatotroph cells. Both drive pituitary GH release but through distinct receptor pathways; ipamorelin is not FDA-approved, tesamorelin is FDA-approved for HIV-associated lipodystrophy.
What the research literature says
The compounds engage two distinct pituitary receptors that both drive GH release through independent signalling cascades — ghrelin-receptor signalling through Gαq/calcium for ipamorelin; GHRH-receptor signalling through Gαs/cAMP for tesamorelin. The two pathways converge on the GH-release machinery downstream without receptor cross-desensitisation, which is the mechanistic basis for combined-research protocols that pair a ghrelin-receptor agonist (ipamorelin) with a GHRH analogue (tesamorelin or CJC-1295).
Structural and regulatory differences: ipamorelin is a 5-amino-acid synthetic pentapeptide developed by Novo Nordisk; tesamorelin is a 44-amino-acid synthetic GHRH analogue developed by Theratechnologies. Tesamorelin is FDA-approved for HIV-associated lipodystrophy (PMID 18057338 Falutz NEJM); ipamorelin is supplied as a research-grade reagent without regulatory approval. The Raun ipamorelin work (PMID 9849822) and the Spooner tesamorelin pharmacotherapy review (PMID 22298602) provide the framing literature for each compound’s pharmacological context.
Researchers comparing the two compounds should anchor the comparison to the receptor-pharmacology distinction rather than treating them as substitutable GH-axis tools. Both can be used together in combined-research protocols engaging both receptor pathways simultaneously.
Why this matters in research context
The comparison matters in peptide-research contexts as a common selection question for GH-axis research. The substantive answer is that the compounds engage different upstream receptors converging on the same GH-release outcome — selection depends on whether the experimental question targets ghrelin-receptor pharmacology specifically or GHRH-receptor pharmacology specifically.
Related compounds
- Ipamorelin 10mg — ghrelin-receptor agonist
- Tesamorelin 10mg — GHRH-receptor agonist
Related research questions
References
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139(5):552-561. [PMID 9849822]
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012;46(2):240-247. [PMID 22298602]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.